Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Tokyo (ots/PRNewswire) - Press release not intended for US and UK media - EU approval paves the way for LIXIANA(R) (edoxaban) to be made available across all European member states - Marketing authorisation is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global ...